{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:50Z","timestamp":1790727110203,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T16:57:46Z","timestamp":1657385866000},"page":"332-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0267","authenticated-orcid":false,"given":"Chiara","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Catania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cocorocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-5851","authenticated-orcid":false,"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5684-5254","authenticated-orcid":false,"given":"Tommaso","family":"de Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2022.06.015_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Consortium APG","year":"2017","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.015_bib2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.06.015_bib3","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.06.015_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","article-title":"Secondary KIT mutations: the GIST of drug resistance and sensitivity","volume":"120","author":"Napolitano","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.06.015_bib5","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.015_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2022.06.015_bib7","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2022.06.015_bib8","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2022.06.015_bib9","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.015_bib10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large-scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.06.015_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.dsi.2013.05.005","article-title":"Characterization of KIT mutation in melanoma","volume":"32","author":"Tzen","year":"2014","journal-title":"Dermatol Sina"},{"issue":"26","key":"10.1016\/j.ejca.2022.06.015_bib12","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2022.06.015_bib13","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.015_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2007.14.0707","article-title":"Major response to imatinib mesylate in KIT-mutated melanoma","volume":"26","author":"Hodi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.06.015_bib15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a Multicenter Trial of Korean Cancer Study Group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2022.06.015_bib16","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/cncr.25766","article-title":"A phase 2 trial of dasatinib in advanced melanoma","volume":"117","author":"Kluger","year":"2011","journal-title":"Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2022.06.015_bib17","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.06.015_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920946158","article-title":"Successful treatment with avapritinib in patient with mucosal metastatic melanoma","volume":"12","author":"Cocorocchio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.06.015_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00008390-200412000-00016","article-title":"Malignant melanoma in Taiwan: a prognostic study of 181 cases","volume":"14","author":"Chang","year":"2004","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.015_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.06.015_bib21","doi-asserted-by":"crossref","first-page":"v748","DOI":"10.1093\/annonc\/mdz266.003","article-title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: preliminary results from a multicenter phase II (REMORA) trial","volume":"30","author":"Itoh","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.06.015_bib22","first-page":"343178","article-title":"Metastatic cerebellar gastrointestinal stromal tumor with obstructive hydrocephalus arising from the small intestine: a case report and review of the literature","volume":"2014","author":"Sato","year":"2014","journal-title":"Case Rep Oncol Med"},{"issue":"28","key":"10.1016\/j.ejca.2022.06.015_bib23","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.015_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.015_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"Moreira","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"44","key":"10.1016\/j.ejca.2022.06.015_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017769","article-title":"Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: a case report","volume":"98","author":"Abdou","year":"2019","journal-title":"Medicine"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:42Z","timestamp":1760733522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"alternative-id":["S0959804922003665"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}